billHR8293Event Wednesday, April 15, 2026Analyzed

Abolish the CMMI Act

Neutral

Summary

HR8293 is an early-stage bill to abolish CMMI with no committee markups, no Senate companion, and no cosponsors. Market impact is negligible at this stage; no tickers meet the confidence threshold for inclusion.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HR8293 is in the earliest legislative stage with zero momentum
  • 2.No cosponsors, no Senate companion, no hearings scheduled
  • 3.Market impact is negligible; no actionable investment thesis exists currently

Market Implications

No material market implications at this stage. If the bill were to advance, potential beneficiaries could include healthcare insurers favoring traditional Medicare fee-for-service ($UNH, $HUM, $CVS) and hospital systems ($HCA, $THC) that may face fewer value-based payment experiments. However, given the bill's current status, no actionable positions are warranted.

Full Analysis

HR8293, the 'Abolish the CMMI Act,' was introduced on April 15, 2026 by Rep. Bean (R-FL) and referred to the House Committees on Energy and Commerce and Ways and Means. The bill would abolish the Center for Medicare and Medicaid Innovation (CMMI) and repeal Section 1115A of the Social Security Act. The bill has no cosponsors, no companion legislation in the Senate, and has not received any committee markups or hearings. As a procedural early-stage bill, its legislative path is uncertain and likely requires significant additional momentum to advance. The bill does not authorize or appropriate any funding. Because CMMI's activities involve testing alternative payment models that can indirectly affect healthcare providers, insurers, and pharmaceutical pricing, any meaningful impact on publicly traded companies would require passage and implementation. At this early stage, the causal chain from bill introduction to specific company revenue impacts is too distant and speculative to meet confidence thresholds for ticker inclusion.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderJun 3, 2026

Implementing Schedule Policy/Career in the Excepted Service

This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.

Exec OrderMay 29, 2026

Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries

This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.

Exec OrderApr 30, 2026

Promoting Efficiency, Accountability, and Performance in Federal Contracting

This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.